The abstract is read at the publisher; the summary is JClub's.
Liver cancer surveillance lacks randomized trial evidence, with most positive results being false positives in low-prevalence populations, limiting support beyond hepatology.
- Why it matters: This gap hampers the development of effective screening programs and prevents broader endorsement by national screening authorities, risking suboptimal patient outcomes.
- What they did: The authors reviewed observational research, acknowledged the absence of randomized trials, and discussed the challenges of current screening modalities, including false positives and weak evidence.
- The result: Advancing risk-based surveillance and gathering stronger evidence could improve detection accuracy and survival benefits, guiding future screening practices and policy support.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.